Light and Laser Therapies for Dermatologic Conditions 8.01.21
Summary
Policy 8.01.21 considers UVB light, PUVA, UVA light, FDA-cleared targeted excimer phototherapy, home UVB phototherapy, 5-aminolevulinic acid photodynamic therapy and pulsed dye laser for port wine birthmarks medically appropriate when the listed criteria are met. It considers targeted phototherapy for first-line treatment of mild psoriasis, generalized psoriasis or psoriatic arthritis, and vitiligo investigational, along with photodynamic therapy with topical preparations for other conditions and light or laser treatment of acne. The current effective date is October 22, 2026, and the 10/22/26 annual review left the policy intent unchanged.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.